List of Excipients in Branded Drug OCTREOTIDE ACETATE

Generic Drugs Containing OCTREOTIDE ACETATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	octreotide acetate	0641-6174	LACTIC ACID, L-
Hikma Pharmaceuticals USA Inc	octreotide acetate	0641-6174	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	octreotide acetate	0641-6174	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	octreotide acetate	0641-6174	WATER

What are the Most Frequently-Used Excipients in OCTREOTIDE ACETATE?

# Of NDCs	Excipient
10	ACETIC ACID
3	LACTIC ACID
3	LACTIC ACID, L-
7	MANNITOL

Last updated: August 22, 2026

Octreotide acetate has three commercial formulation segments: immediate-release injection, long-acting intramuscular depot, and oral capsules. The strongest excipient opportunities are in depot microspheres, permeation-enhanced oral delivery, preservative-free multidose systems, and differentiated ready-to-use presentations. Generic injection competition is established, while long-acting and oral products remain more difficult because release kinetics, absorption enhancement, device performance, and clinical bridging create substantial development barriers.

Octreotide Acetate Excipient Strategy and Commercial Opportunities

What formulations of octreotide acetate are commercially important?

Octreotide acetate is a somatostatin analogue used primarily for acromegaly and symptom control in neuroendocrine tumors and related secretory disorders. Commercial products use three delivery approaches.

Product or formulation	Route	Main formulation challenge	Commercial status
Immediate-release octreotide acetate injection	Subcutaneous or intravenous	Chemical stability, acidic pH, injection tolerability, multidose preservation	Generic competition
Sandostatin LAR Depot	Intramuscular	Microsphere loading, burst control, four-week release, reconstitution	Branded long-acting product
Mycapssa	Oral capsule	Low intestinal permeability, enzymatic degradation, food effects, absorption variability	FDA-approved oral product

Sandostatin injection contains octreotide acetate with excipients including mannitol, lactic acid, sodium chloride, and sodium bicarbonate for pH adjustment. Sandostatin LAR uses poly(DL-lactide-co-glycolide), carboxymethylcellulose sodium, mannitol, and a diluent containing carboxymethylcellulose sodium, mannitol, polysorbate 80, and water for injection.[1]

Mycapssa uses an oral delivery system intended to improve octreotide absorption across the gastrointestinal tract. Its formulation includes the permeation-enhancing excipient sodium caprate, also known as C10, together with capsule and coating components.[2]

Which excipients are most important for octreotide acetate?

The excipient strategy depends on whether the product is an injection, depot microsphere, or oral capsule. Octreotide is a peptide, so excipient selection must control degradation, adsorption, aggregation, release rate, and epithelial transport.

Immediate-release injectable excipients

The injectable product has relatively simple composition but strict quality requirements.

Key functions include:

• Mannitol provides tonicity adjustment and can support solution stability.
• Lactic acid helps establish an acidic formulation environment.
• Sodium chloride contributes to tonicity.
• Sodium bicarbonate permits pH adjustment.
• Water for injection is the vehicle.
• Preservatives may be used in multidose presentations, but preservative-free formats have commercial value for sensitive patients and institutional use.

The target pH is acidic. This supports chemical stability but can contribute to injection-site discomfort. Commercial opportunities therefore exist for products that reduce injection volume, improve buffering, offer prefilled syringes, or provide a less painful subcutaneous presentation without changing the approved route or exposure profile.

Potential development risks include peptide adsorption to glass or polymer surfaces, particulate formation, extractables and leachables from delivery devices, and changes in impurity profiles caused by pH or oxygen exposure.

Long-acting microsphere excipients

Sandostatin LAR is a depot formulation based on biodegradable PLGA microspheres. PLGA provides the release matrix and hydrolyzes over time into lactic and glycolic acid.

The core formulation variables are:

• Polymer molecular weight and lactide-to-glycolide ratio
• Microsphere particle-size distribution
• Porosity and internal morphology
• Drug loading
• Surface morphology
• Residual solvent level
• Reconstitution behavior
• Initial burst release
• Four-week cumulative release
• Syringeability and needle force

Carboxymethylcellulose sodium and mannitol in the diluent influence suspension viscosity, wetting, and injectability. Polysorbate 80 can improve wetting and reduce interfacial adsorption, but it introduces its own oxidation and peroxide-control requirements.

The main commercial opportunity is a ready-to-use or simplified reconstitution depot. Any new product must demonstrate comparable clinical exposure, release duration, injection performance, and safety. A formulation that matches average pharmacokinetics but produces a materially different early burst or late-release tail may still face regulatory and clinical barriers.

Oral permeation-enhanced excipients

Oral delivery is the highest-value excipient opportunity because peptide absorption is ordinarily low. Sodium caprate is used as a transient permeation enhancer. It can increase paracellular or transcellular transport by altering epithelial barrier properties.

The central development issues are:

• Local tolerability in the gastrointestinal tract
• Dose-dependent absorption
• Food and meal-composition effects
• Capsule dissolution location
• Enteric protection
• Peptide degradation before release
• Batch-to-batch content uniformity
• Variability between patients
• Chronic-use safety of the permeation enhancer

Alternative excipient strategies include medium-chain fatty acids, bile-salt-based systems, mucoadhesive polymers, self-emulsifying systems, lipid nanoparticles, and enzyme-inhibitor combinations. These approaches may improve absorption, but they generally create more complex regulatory packages than an immediate-release capsule.

For octreotide, the best commercial strategy is likely a targeted oral system rather than a broad reformulation program. The product must demonstrate a clinically meaningful reduction in injection burden while preserving disease control and minimizing dose titration.

What excipient strategies have the strongest commercial potential?

1. Ready-to-use long-acting injections

A ready-to-use or minimally prepared octreotide depot could compete on administration simplicity, reduced preparation errors, and improved clinic throughput.

Commercially attractive attributes include:

• Pre-mixed suspension
• Pre-filled dual-chamber syringe
• Smaller injection volume
• Smaller needle gauge
• Stable refrigerated or controlled-room-temperature storage
• Reduced resuspension time
• Lower injection-site pain
• Consistent delivery from community clinics

The technical barrier is high because the delivery system must preserve the release profile of the reference depot. A change in polymer, surfactant, diluent, or reconstitution method can alter microsphere hydration and release kinetics.

2. Oral capsules with improved absorption consistency

An oral product with lower pharmacokinetic variability could improve persistence and reduce rescue injections. Opportunities include optimizing sodium caprate concentration, capsule coating, gastric protection, and dosing instructions.

The best target is not necessarily maximum absorption. Excessive permeation can increase gastrointestinal exposure and local tolerability risk. The commercial target is predictable exposure at the lowest effective enhancer level.

3. Lower-volume subcutaneous injection

A concentrated immediate-release product could reduce injection burden for patients who require repeated dosing. The formulation would need to address:

• Increased peptide concentration
• Viscosity
• Aggregation
• Osmolality
• Injection-site tolerability
• Device compatibility
• Dose accuracy

A high-concentration formulation may support an autoinjector or prefilled pen. This could create differentiation even where the active ingredient is generic.

4. Pediatric and small-dose presentations

Low-dose prefilled syringes and unit-dose cartridges can reduce measurement error and waste. This opportunity is relevant to patients requiring individualized titration or intermittent symptom control.

Unit-dose packaging also reduces preservative exposure and may appeal to specialty pharmacies and home administration programs.

5. Temperature-stable formulations

Octreotide products are generally distributed under controlled storage conditions. Lyophilized, polymeric, or stabilized liquid formulations that tolerate short temperature excursions could reduce cold-chain costs and improve use in decentralized care.

Temperature stability is commercially useful only if it does not compromise reconstitution, release kinetics, or peptide purity.

What patents protect octreotide acetate formulations?

Octreotide acetate itself is an old active ingredient, so basic composition-of-matter protection has expired in major markets. Current patent value is concentrated in formulation, delivery, manufacturing, and method-of-use claims.

Immediate-release injection patents

The basic injectable formulation is vulnerable to generic competition because the composition is relatively simple and the reference product has long market experience. Generic applicants can generally pursue abbreviated approval if they satisfy pharmaceutical equivalence and bioequivalence requirements.

Residual value may remain in:

• Prefilled delivery systems
• Concentrated solutions
• Preservative-free multidose systems
• Device-specific dose-control mechanisms
• Stability-improving packaging
• New administration schedules

Depot formulation patents

The most defensible IP generally concerns:

• PLGA composition
• Microsphere size and morphology
• Drug loading
• Manufacturing conditions
• Release-rate specifications
• Reconstitution systems
• Extended dosing intervals
• Combination of polymer and excipient components

These claims are difficult to design around if the clinical performance depends on a narrow release window. However, a competitor may pursue a different biodegradable polymer, alternate microsphere process, in situ depot, or implantable delivery system.

Oral formulation patents

Oral octreotide patents are likely to have the highest commercial relevance among newer formulations. Claim categories can include:

• Octreotide plus sodium caprate
• Specific enhancer-to-drug ratios
• Enteric or delayed-release coatings
• Capsule dissolution profiles
• Food-restricted administration
• Treatment of acromegaly or neuroendocrine tumors
• Pharmacokinetic exposure ranges
• Manufacturing processes for peptide loading

Mycapssa was approved by the FDA in 2020 as an oral octreotide product for long-term maintenance treatment in adults who responded to and tolerated octreotide or lanreotide.[2] The product’s commercial protection is therefore more dependent on formulation and method-of-use rights than on the active ingredient.

Patent status changes through expiration, terminal disclaimers, patent-term adjustment, Orange Book updates, litigation, and settlements. The FDA Orange Book should be treated as the controlling source for currently listed patents and regulatory exclusivity for approved drug products.[3]

When does octreotide acetate lose exclusivity?

Octreotide acetate has already lost basic active-ingredient exclusivity. Market protection differs by product.

Protection category	Octreotide acetate position
Active ingredient	Expired in major jurisdictions
Immediate-release injection	Generic competition established
Long-acting depot	Formulation and manufacturing barriers remain important
Oral formulation	Newer formulation and method-of-use patents are the main protection
Orphan-drug exclusivity	Depends on indication and product-specific designation
Regulatory exclusivity	Product-specific and separate from patent expiry

The key commercial distinction is between legal expiry and practical entry. A generic may face no blocking composition patent but still encounter technical barriers involving microsphere release, device performance, clinical bridging, and manufacturing reproducibility.

What is the Orange Book status of octreotide acetate products?

The Orange Book lists patents and exclusivity associated with approved U.S. drug products, including branded octreotide formulations. Immediate-release octreotide acetate injection products have generic competition, while newer oral products rely on formulation-specific protection.

A patent analyst should separate four questions:

1. Is the patent listed for the exact reference product?
2. Does the claim cover the proposed generic or follow-on formulation?
3. Has the patent expired or received patent-term adjustment?
4. Has the applicant filed a Paragraph IV certification?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. The reference sponsor may sue within 45 days, which can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions.[4]

For octreotide, Paragraph IV exposure is more likely to concentrate on oral and depot products than on conventional injection. A generic injection applicant can often rely on established bioequivalence pathways, while a complex depot applicant may require additional comparative performance and clinical evidence.

Which companies are challenging octreotide acetate products?

Generic manufacturers have entered the immediate-release octreotide injection market. The competitive field includes large injectable generic companies and specialty manufacturers with sterile fill-finish capacity.

The long-acting and oral segments have a different structure:

• Novartis controls the Sandostatin and Sandostatin LAR reference franchises.
• Chiasma developed Mycapssa, which was later commercialized through ownership changes involving Amryt and Chiesi.
• Generic companies may target immediate-release injection first because of lower development complexity.
• Specialty pharmaceutical companies may target oral delivery, depot products, or device-enabled reformulations.

Competition is not limited to identical octreotide products. Lanreotide, sold as Somatuline Depot by Ipsen, competes directly in acromegaly and neuroendocrine tumor treatment. The relevant commercial question is often whether a new octreotide presentation can displace an established long-acting somatostatin analogue rather than whether it can replace generic injection.

What generic entry risks exist for octreotide acetate?

Immediate-release injection

Generic entry risk is high. The formulation uses conventional injectable excipients, and multiple manufacturers can produce sterile octreotide acetate solutions. Price erosion, hospital contracting, and supply reliability are likely to determine market share.

Long-acting depot

Generic entry risk is moderate but technically complex. The key barriers are:

• Demonstrating comparable release
• Matching injection-site exposure
• Controlling polymer degradation
• Reproducing microsphere morphology
• Establishing an efficient clinical bridging strategy
• Manufacturing at commercial scale

A successful follow-on depot could create substantial price pressure because long-acting products carry higher treatment costs than simple injection.

Oral octreotide

Generic entry risk is lower in the near term than for injection. An applicant must generally reproduce the absorption-enhancing system and show that differences in excipient composition do not alter efficacy, safety, food effects, or exposure.

A non-identical oral formulation may instead pursue a new drug application or a 505(b)(2) pathway, depending on the extent of reliance on existing findings.[5]

How strong is the octreotide acetate patent estate?

The estate is strongest where formulation performance is difficult to reproduce and weakest where the product is a conventional aqueous injection.

Segment	Patent strength	Manufacturing barrier	Generic risk
Immediate-release injection	Low to moderate	Moderate sterile manufacturing barrier	High
PLGA depot	Moderate to strong	High	Moderate
Oral permeation-enhanced capsule	Moderate to strong	Moderate to high	Lower near term
Prefilled syringe or autoinjector	Product-specific	Moderate	Depends on device claims
Temperature-stable liquid	Potentially strong if clinically differentiated	High stability burden	Lower if meaningfully differentiated

Patent strength depends on claim breadth, validity, written-description support, enablement, prosecution history, and the degree to which the claim captures a commercially necessary formulation feature. A narrow claim to one enhancer ratio may be easier to design around than a broader claim tied to a clinically defined exposure profile, but broad pharmacokinetic claims face their own validity and infringement challenges.

What manufacturing and IP barriers affect commercial entry?

The principal manufacturing barriers are not the synthesis of octreotide acetate. They are formulation control and scale-up.

For injectables, the critical controls are sterile processing, peptide recovery, particulate limits, container closure integrity, and preservative consistency.

For PLGA microspheres, the critical controls include emulsification, solvent removal, particle sizing, drug distribution, residual solvent, release testing, and reconstitution.

For oral capsules, the critical controls include peptide content uniformity, enhancer distribution, capsule dissolution, coating integrity, moisture protection, and stability under gastrointestinal conditions.

Process patents may create meaningful barriers even when composition patents are weak. A competitor that uses a different emulsification or encapsulation process may avoid infringement but face higher development risk and a longer comparability program.

How does octreotide compare with lanreotide?

Octreotide and lanreotide are both long-acting somatostatin analogues. Their commercial differentiation depends on dosing interval, administration setting, injection device, indication, patient response, and contracting.

Attribute	Octreotide	Lanreotide
Immediate-release option	Established	Limited relative to octreotide
Long-acting product	Sandostatin LAR, intramuscular	Somatuline Depot, deep subcutaneous
Oral product	Mycapssa	No widely established oral counterpart
Excipient opportunity	Depot, oral absorption, injection devices	Depot optimization and device differentiation
Generic vulnerability	High for injection, lower for complex products	Complex depot barriers remain

An oral octreotide product can compete by removing injections, but its value depends on adherence, gastrointestinal tolerability, dose frequency, and payer coverage. A new depot product must compete against both established clinical practice and provider familiarity.

What licensing opportunities exist for octreotide excipients and delivery systems?

Licensing targets fall into four groups:

1. Permeation-enhancer platforms with peptide-specific safety data.
2. PLGA or alternative biodegradable depot technologies with validated release control.
3. Prefilled and autoinjector systems compatible with concentrated octreotide solutions.
4. Stabilizing excipients and packaging systems that extend shelf life or reduce cold-chain dependence.

The most attractive deal structure would typically combine an excipient or delivery platform with a defined octreotide development program. Platform owners should seek claims covering the excipient combination, manufacturing process, dosage form, and treatment method.

For a generic manufacturer, licensing a delivery device or depot process may reduce development time but increase royalty burden. For a specialty company, acquiring oral or depot rights can provide a faster route into an established orphan and specialty-care market than developing a new peptide.

What FDA regulatory pathway applies to new octreotide formulations?

The pathway depends on the degree of formulation change.

• An ANDA is most suitable for a conventional generic injection that meets applicable equivalence requirements.
• A 505(b)(2) application may be suitable for a reformulated injection, new dosage form, new route, or modified release product that relies partly on FDA findings for an approved octreotide product.
• A full 505(b)(1) application may be required where the delivery technology creates substantial uncertainty about safety or efficacy.
• An abbreviated pathway for a complex depot depends on FDA-specific expectations for comparative release, pharmacokinetics, and clinical evidence.

FDA approval of Mycapssa illustrates the regulatory value of a new oral delivery approach, but it also demonstrates that excipient innovation must be supported by clinical evidence, not only in vitro dissolution or permeability data.[2]

Key Takeaways

• Immediate-release octreotide acetate injection is exposed to substantial generic competition.
• The highest-value excipient opportunities are oral permeation enhancement, long-acting depot optimization, and ready-to-use injection systems.
• Sodium caprate is commercially important because it addresses the central barrier to oral peptide absorption.
• PLGA microsphere products have stronger technical barriers than conventional injections, but they require demanding release and manufacturing controls.
• Basic octreotide composition protection has expired; current value is concentrated in formulation, device, process, and method-of-use patents.
• Paragraph IV risk is highest for newer oral and depot products, not for conventional injectable products.
• Lanreotide remains the primary branded long-acting competitive reference.
• The most practical commercial entry routes are generic injection, 505(b)(2) reformulation, licensed oral delivery, and differentiated depot technology.

FAQs

Can sodium caprate be used in a new oral octreotide product?

Yes, but a new product using sodium caprate would need to address formulation-specific patent claims, enhancer concentration, gastrointestinal tolerability, food effects, and regulatory equivalence or reliance requirements.

What is the best excipient opportunity for a generic octreotide manufacturer?

A ready-to-use concentrated injection or differentiated prefilled presentation offers a more accessible opportunity than a new oral or PLGA depot formulation. The product would still need to demonstrate stability, device compatibility, injection performance, and regulatory equivalence.

Can a new octreotide depot avoid PLGA patents?

Potentially. A sponsor could use another biodegradable polymer, an in situ forming depot, an implant, or a different microsphere process. Avoiding a patent claim would not eliminate the need to demonstrate comparable exposure and clinically acceptable release.

Are preservatives necessary in octreotide acetate injections?

Not necessarily. Preservative-free unit-dose or prefilled products are possible, but multidose presentations may require antimicrobial protection unless the container and administration system support another validated approach.

Is oral octreotide commercially superior to injectable octreotide?

Oral octreotide has a strong convenience advantage, but commercial superiority depends on adherence, absorption variability, gastrointestinal tolerability, payer access, and the ability to maintain disease control without frequent dose adjustments.

References

1. Novartis Pharmaceuticals Corporation. (2023). Sandostatin injection and Sandostatin LAR Depot prescribing information. U.S. Food and Drug Administration.

2. Chiasma, Inc. (2020). Mycapssa prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov

5. U.S. Food and Drug Administration. (2023). Applications covered by Section 505(b)(2). https://www.fda.gov